Literature DB >> 9414172

Hepatocellular carcinoma: from gene to public health.

R Montesano1, P Hainaut, C P Wild.   

Abstract

Liver diseases associated with chronic hepatitis B virus (HBV) infection, including hepatocellular carcinoma, account for more than 1 million deaths annually worldwide. In addition to HBV infection, other risk factors are involved in the etiology of hepatocellular carcinoma and, among these, dietary exposure to the carcinogenic aflatoxins is of particular importance in certain regions of southeast Asia and sub-Saharan Africa. The relative contributions of these two risk factors and the mechanism of the interaction between them in the pathogenesis of hepatocellular carcinoma are still poorly understood. The recently developed individual biochemical and molecular markers of aflatoxin exposure, i.e., aflatoxin-albumin adducts in blood and a specific GC to TA transversion mutation in codon 249 of the p53 gene (249ser p53 mutation) in hepatocellular carcinomas, permit a better quantitative estimation of aflatoxin exposure in different populations of the world. A comprehensive summary of the data from our laboratory and the literature, based on a large number (>1000) of individual cases of hepatocellular carcinoma, is presented here and shows the following: 1) A high level and high prevalence of exposure to aflatoxins occur in West Africa, Mozambique, and some regions of China; 2) a high prevalence of the 249ser p53 mutation is detected in these countries; and 3) hepatocellular carcinomas from countries with low or no exposure to aflatoxins show a very low prevalence of the 249ser p53 mutation and distinctly different p53 mutation spectra, probably indicating different etiologies. Experimental and epidemiologic studies demonstrate an interaction between HBV infection and aflatoxins in hepatocarcinogenesis. The relevance of the biochemical/molecular markers of aflatoxin exposure, HBV vaccination, and the reduction of aflatoxin exposure, in addition to the interaction between HBV infection and other risk factors in liver carcinogenesis, are discussed with regard to the implementation of measures for primary prevention.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9414172     DOI: 10.1093/jnci/89.24.1844

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  47 in total

1.  Determination of amino acid pairs in human p53 protein sensitive to mutations/variants by means of a random approach.

Authors:  Guang Wu; Shaomin Yan
Journal:  J Mol Model       Date:  2003-08-30       Impact factor: 1.810

2.  Dietary aflatoxin exposure and impaired growth in young children from Benin and Togo: cross sectional study.

Authors:  Y Y Gong; K Cardwell; A Hounsa; S Egal; P C Turner; A J Hall; C P Wild
Journal:  BMJ       Date:  2002-07-06

3.  Integrin gene expression profiles of human hepatocellular carcinoma.

Authors:  Lian-Xin Liu; Hong-Chi Jiang; Zhi-Hua Liu; Jing Zhou; Wei-Hui Zhang; An-Long Zhu; Xiu-Qin Wang; Min Wu
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

4.  Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection.

Authors:  H Huang; H Fujii; A Sankila; B M Mahler-Araujo; M Matsuda; G Cathomas; H Ohgaki
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

Review 5.  Tumor suppressor and hepatocellular carcinoma.

Authors:  Juliette Martin; Jean-Francois Dufour
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

6.  Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver.

Authors:  X R Xu; J Huang; Z G Xu; B Z Qian; Z D Zhu; Q Yan; T Cai; X Zhang; H S Xiao; J Qu; F Liu; Q H Huang; Z H Cheng; N G Li; J J Du; W Hu; K T Shen; G Lu; G Fu; M Zhong; S H Xu; W Y Gu; W Huang; X T Zhao; G X Hu; J R Gu; Z Chen; Z G Han
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

7.  Combining antiangiogenic therapy with immunotherapy exerts better therapeutical effects on large tumors in a woodchuck hepatoma model.

Authors:  Kai-Wen Huang; Hui-Lin Wu; Hsiu-Lin Lin; Po-Chin Liang; Pei-Jer Chen; Shih-Hui Chen; Hsin-I Lee; Pei-Yi Su; Wen-Hsuan Wu; Po-Huang Lee; Lih-Hwa Hwang; Ding-Shinn Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-02       Impact factor: 11.205

Review 8.  The clinical role of 'liquid biopsy' in hepatocellular carcinoma.

Authors:  Jessica A Howell; Rohini Sharma
Journal:  Hepat Oncol       Date:  2015-11-30

9.  Serum p53 gene polymorphisms and severity of hepatitis B or C-related chronic liver diseases in Taiwan.

Authors:  Yone-Han Mah; Ching-Sheng Hsu; Chen-Hua Liu; Chun-Jen Liu; Ming-Yang Lai; Pei-Jer Chen; Ding-Shinn Chen; Jia-Horng Kao
Journal:  Hepatol Int       Date:  2011-02-06       Impact factor: 6.047

10.  Generational risks for cancers not related to tobacco, screening, or treatment in the United States.

Authors:  Yueh-Ying Han; Devra L Davis; Joel L Weissfeld; Gregg E Dinse
Journal:  Cancer       Date:  2010-02-15       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.